United States takes 1/3 of the global healthcare market, which is estimated to be 1.48 trillion U.S. dollars. However, the U.S. health policy landscape is rapidly evolving, with significant changes such as the Inflation React Act (IRA) empowering public payers to negotiate drug prices, and a major overhaul of Pharmacy Benefit Managers (PBM) and pharmacy operation models. To navigate these complexities, we collaborate with our partners to assist both large and small biopharmaceutical and medical device companies worldwide in planning their market access and reimbursement strategies. Our goal is to ensure that these companies are well-positioned to succeed in this dynamic and highly competitive market.